Beta

Harvard bioscience, inc.HBIO.US Overview

US StockHealthcare
(No presentation for HBIO)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

HBIO AI Insights

HBIO Overall Performance

HBIO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

HBIO Recent Performance

-3.18%

Harvard bioscience, inc.

-1.64%

Avg of Sector

-0.21%

S&P500

HBIO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check HBIO's Trend

HBIO Key Information

HBIO Valuation Metrics

HBIO Profile

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

Price of HBIO

HBIO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

HBIO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-12.68
PE Ratio (TTM)
-
Forward PE
15.06
PS Ratio (TTM)
0.36
PB Ratio
2.23
Price-to-FCF
5.74
METRIC
VALUE
vs. INDUSTRY
Gross Margin
57.67%
Net Margin
-65.51%
Revenue Growth (YoY)
-8.06%
Profit Growth (YoY)
-8.87%
3-Year Revenue Growth
-5.84%
3-Year Profit Growth
-3.63%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-12.68
PE Ratio (TTM)
-
Forward PE
15.06
PS Ratio (TTM)
0.36
PB Ratio
2.23
Price-to-FCF
5.74
Gross Margin
57.67%
Net Margin
-65.51%
Revenue Growth (YoY)
-8.06%
Profit Growth (YoY)
-8.87%
3-Year Revenue Growth
-5.84%
3-Year Profit Growth
-3.63%

  • When is HBIO's latest earnings report released?

    The most recent financial report for Harvard bioscience, inc. (HBIO) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating HBIO's short-term business performance and financial health. For the latest updates on HBIO's earnings releases, visit this page regularly.

  • What is the operating profit of HBIO?

    According to the latest financial report, Harvard bioscience, inc. (HBIO) reported an Operating Profit of 1.71M with an Operating Margin of 7.2% this period, representing a growth of 15,445.45% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is HBIO's revenue growth?

    In the latest financial report, Harvard bioscience, inc. (HBIO) announced revenue of 23.74M, with a Year-Over-Year growth rate of -3.34%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does HBIO have?

    At the end of the period, Harvard bioscience, inc. (HBIO) held Total Cash and Cash Equivalents of 8.61M, accounting for 0.11 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does HBIO go with three margins increasing?

    In the latest report, Harvard bioscience, inc. (HBIO) did not achieve the “three margins increasing” benchmark, with a gross margin of 59.7%%, operating margin of 7.2%%, and net margin of -12%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess HBIO's profit trajectory and future growth potential.

  • Is HBIO's EPS continuing to grow?

    According to the past four quarterly reports, Harvard bioscience, inc. (HBIO)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.6. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of HBIO?

    Harvard bioscience, inc. (HBIO)'s Free Cash Flow (FCF) for the period is -695K, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 155.2% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.